PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)
批准号:
9316472
负责人:
PETER VOORHEES
金额:
$14.07万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AmendmentAreaBasic ScienceBiometryCancer CenterCancer Center Support GrantCancer PatientClinical Cancer CenterClinical DataClinical ProtocolsClinical ResearchClinical Research ProtocolsClinical SciencesClinical TrialsDiseaseDocumentationElementsEnsureEnvironmentFacultyFlowchartsFrequenciesGoalsHemeHumanInstitutional Review BoardsIntervention TrialInvestmentsMalignant NeoplasmsModificationMonitorNorth CarolinaOnline SystemsPatient riskPopulation SciencesProcessProtocols documentationRadiation OncologyResearchResearch EthicsResearch InfrastructureResourcesReview CommitteeSystemTimeUNC Lineberger Comprehensive Cancer CenterUniversitiesauthoritycancer clinical trialcost effectivedata managementmemberresearch study
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract – Protocol Review and Monitoring System (PRMS)
The UNC Lineberger Comprehensive Cancer Center's PRMS facilitates internal oversight of the scientific
aspects of all cancer clinical trials at the University of North Carolina focusing on the scientific merit, priorities,
and progress of clinical protocol research. The system is a multi-step process with preliminary review by
Protocol Office Disease teams (PODs) and the Protocol Office Executive Committee (POEC), followed by a
formal review by the Protocol Review Committee (PRC).
The PRC is chaired by Peter Voorhees, MD, and meets bi-monthly to review every cancer-related clinical
protocol before it is submitted to The Office of Human Research Ethics' Institutional Review Board (IRB). The
PRC's primary function is to ensure the scientific quality of proposed studies. As described in Clinical Protocol
and Data Management (CPDM), PODs and POEC review protocols for feasibility, quality, and priority before
they are submitted to the PRC. The PRC monitors study accrual and has the authority to close under-
performing trials. During 2014, the PRC reviewed 295 protocols -- 112 new studies and 183 active trials for
renewal and monitoring.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: PX-171-001-PHASE I STUDY OF ESCALATING DOSES OF PROTEASOME INHIB
-
批准号:7716842
-
项目类别:
-
资助金额:$0.42万
-
财政年份:2008
-
负责人:PETER VOORHEES
-
依托单位:
LCCC 0406: ADDITION OF CELLCEPT TO GLEEVEC IN THE TREATMENT OF LEUKEMIA
-
批准号:7625608
-
项目类别:
-
资助金额:$0.02万
-
财政年份:2006
-
负责人:PETER VOORHEES
-
依托单位:
LCCC 0406: ADDITION OF CELLCEPT TO GLEEVEC IN THE TREATMENT OF LEUKEMIA
-
批准号:7377561
-
项目类别:
-
资助金额:$0.4万
-
财政年份:2005
-
负责人:PETER VOORHEES
-
依托单位:
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)
-
批准号:9617386
-
项目类别:
-
资助金额:$0.21万
-
财政年份:--
-
负责人:PETER VOORHEES
-
依托单位:
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)
-
批准号:9391979
-
项目类别:
-
资助金额:$14.34万
-
财政年份:--
-
负责人:PETER VOORHEES
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: